IDIQ for medical writers
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 75F40122D00018
- Awardee
-
Kaiva Strategies, LLC UEI HCWKVFGBPA64
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Task orders
- 9 $11,171,896 obligated
Award facts
- Opportunity
-
- 75F40122R00040 Solicitation number
- Combined order value
-
- $11,171,896 Current, with exercised options
- $17,144,552 Potential, with all options
- Last date to order 86% complete
- IDV ceiling 51% used
- $22,000,000.00
- Maximum order
- $5,000,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- Set-aside
- 8(a) Sole Source
- Competition
- Not Available for Competition · 1 offer Only One Source
- Pricing
- Order Dependent (IDV only)
Award details come from SAM.gov/FPDS.
About this IDV
The Food and Drug Administration awarded an 8(a) sole-source indefinite-delivery contract to Kaiva Strategies, LLC on July 1, 2022, with a $22 million ceiling and ultimate completion date of June 30, 2027. This is a single-award contract reserved for the 8(a) Business Development Program. Kaiva Strategies is a tribally-owned, minority-owned small business certified under the 8(a) program through August 2, 2025.
Place of performance is Silver Spring, Maryland. The IDIQ procures medical writing support, including scientific writers-editors and regulatory communication services across multiple FDA program offices and centers.
The period of performance runs from award through June 30, 2027. The contract structure establishes a $22 million ceiling with no stated minimum guarantee.
Under this vehicle, the FDA has issued eight delivery orders totaling approximately $8.7 million in combined potential value. Notable recent orders include a $1.358 million delivery order issued July 9, 2024 (ultimate completion July 31, 2025) for scientific writing support to FDA program offices, and a $1.185 million delivery order issued May 10, 2024 (ultimate completion May 14, 2025) for medical writer support. Earlier orders supporting specific FDA centers—including the Office of Vaccines Research and Review, Office of Tissues and Advanced Therapies, Office of Biostatistics and Pharmacovigilance, and Division of Vaccines and Related Biological Products Advisory—were issued at award on July 1, 2022 and June 30, 2023. All delivery orders use labor-hour pricing and are performed on an 8(a) sole-source basis. Kaiva operates as a managed service delivery vehicle, with subcontractors performing the majority of contractor hours across issued orders.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Novation Agreement | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75F40122D00018?
75F40122D00018 was awarded to Kaiva Strategies, LLC by Food and Drug Administration (Department of Health and Human Services) on July 1, 2022.
How much is contract 75F40122D00018 worth?
Orders under 75F40122D00018 have obligated $11,171,896. Their combined potential value, with all options, is $17,144,552. 75F40122D00018's own ceiling is $22,000,000. A single order can be worth up to $5,000,000.
How many orders have been placed under contract 75F40122D00018?
9 orders have been placed under 75F40122D00018, the latest on September 28, 2026.
Who can order from contract 75F40122D00018?
75F40122D00018 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75F40122D00018 competed?
The extent of competition for 75F40122D00018 was not available for competition. The government received 1 offer. It was set aside: 8(a) Sole Source.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV